Abstracts tagged "morbidity and mortality and rheumatoid arthritis (RA)"

Abstract Number: 2053 • 2014 ACR/ARHP Annual Meeting
Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study
Joëlle van den Hoek^1,2, Hendriek C. Boshuizen³, Leo D. Roorda⁴, Gerard J. Tijhuis⁵, Mike T. Nurmohamed⁵, Trudi van den Bos² and Joost Dekker^6,7, ¹Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, ²Social Medicine, Academic Medical Center, Amsterdam, Netherlands, ³National Institute of Public Health and the Environment, Bilthoven, Netherlands, ⁴Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁷Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher mortality risk than the general population, with similar patterns over the last decades. However, more recent…
Abstract Number: 1416 • 2014 ACR/ARHP Annual Meeting
Analysis of Cardiac Involvement in Patients with Amyloid a (AA) Amyloidosis Due to Rheumatoidarthritis
Daisuke Kobayashi¹, Satoshi Ito¹, Satoru Kodama¹, Akira Murasawa¹, Ichiei Narita² and Kiyoshi Nakazono¹, ¹Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose Rheumatoid arthritis (RA) is one of the major causes of amyloid A (AA) amyloidosis. The major organs affected are the kidneys and gastrointestinal (GI)…
Abstract Number: 1068 • 2014 ACR/ARHP Annual Meeting
Smoking-Related Mortality in Rheumatoid Arthritis: A Retrospective Cohort Study Using Electronic Medical Records
Rebecca M Joseph¹, Mohammad Movahedi² and Deborah PM Symmons^1,2, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Smoking is a known risk factor for rheumatoid arthritis (RA) and there is evidence suggesting that many patients with RA continue to smoke. The…
Abstract Number: 1770 • 2013 ACR/ARHP Annual Meeting
All-Cause Mortality For Patients with Rheumatoid Arthritis In a Universal Public Health Care System
Jessica Widdifield^1,2, J. Michael Paterson¹, Sasha Bernatsky³, Bindee Kuriya⁴, J. Carter Thorne⁵, Simon Hollands¹ and Claire Bombardier⁶, ¹Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Studies evaluating trends in rheumatoid arthritis (RA) mortality over time have produced inconsistent results. Our aim was to estimate all-cause mortality in RA between…
Abstract Number: 1052 • 2013 ACR/ARHP Annual Meeting
Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study
Diane Lacaille¹, J. Antonio Avina-Zubieta^2,3, Eric C. Sayre², Michal Abrahamowicz⁴ and John Esdaile^1,5, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Glucocorticosteroids (GC) are frequently used in the management of rheumatoid arthritis (RA). Due to their metabolic and immunosuppressive effects, they could increase the risk…
Abstract Number: 779 • 2013 ACR/ARHP Annual Meeting
Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients — A Nationwide Register Study 2000—2008
Anne M. Kerola¹, Tuomo Nieminen², Lauri J. Virta³, Hannu Kautiainen⁴, Kari Puolakka⁵, Tuomas Kerola⁶, Timo Pohjolainen⁷ and Markku J. Kauppi⁶, ¹Medical School, University of Helsinki, Helsinki, Finland, ²Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ³Research Department, the Social Insurance Institution, Turku, Finland, ⁴Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁵Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ⁶Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁷ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland
Background/Purpose: Increased cardiovascular (CV) mortality in established rheumatoid arthritis (RA) is a widely accepted threat, but in early RA or inception cohorts, growing evidence suggests…
Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Diane Lacaille¹, Michal Abrahamowicz², Eric C. Sayre³ and John Esdaile⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…
Abstract Number: 1245 • 2012 ACR/ARHP Annual Meeting
Age-Specific Association Between Disease-Related Measures and Incident Cardiovascular Events and All-Cause Mortality in Early Rheumatoid Arthritis
Sofia Ajeganova¹, Maria LE Andersson², Johan Frostegård³ and Ingiäld Hafström¹, ¹Karolinska Institutet, Unit of Rheumatology, Department of Medicine Huddinge, Stockholm, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden
Background/Purpose: Increased risk of cardiovascular disease (CVD) and premature mortality in rheumatoid arthritis (RA) has been established, but the impact of inflammatory and disease related…
Abstract Number: 822 • 2012 ACR/ARHP Annual Meeting
Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis
Shreyasee Amin¹, Sherine E. Gabriel², Sara J. Achenbach³, Elizabeth J. Atkinson³ and L. Joseph Melton III⁴, ¹Rheumatology and Health Sciences Research, Mayo Clinic, Rochester, MN, ²Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Department of Hlth Sciences, Mayo Clinic, Rochester, MN
Background/Purpose: Women and men with RA are at an increased risk for fracture [fx] as well as greater overall mortality. It is recognized that in…
Abstract Number: 767 • 2012 ACR/ARHP Annual Meeting
Patients with Early Inflammatory Arthritis Who Fulfil the 2010 American College Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis Have Increased Mortality Compared to Those Who Do Not: Results From the Norfolk Arthritis Register
Jh Humphreys¹, Suzanne Verstappen², Mark Lunt³, Jackie Chipping⁴, Kimme Hyrich⁵, Tarnya Marshall⁶ and Deborah Symmons⁷, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁴Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁶Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁷Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA) in comparison with the general population. The majority of studies have used the 1987 ACR criteria to…
Abstract Number: 357 • 2012 ACR/ARHP Annual Meeting
Is the Impact of Methotrexate On Mortality in Rheumatoid Arthritis Independent of Its Effect On Disease Activity?
Dietmar MJ Krause¹, Bernadette Gabriel², Gertraud Herborn³ and Rolf Rau⁴, ¹Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, ²Private Practice, Gladbeck, Germany, ³Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany, ⁴Evangelisches Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA). MTX shows effects on disease activity, radiologic progression and mortality. These…
Abstract Number: 87 • 2012 ACR/ARHP Annual Meeting
Prediction of Mortality in Rheumatoid Arthritis Using a Serum Cytokine Profile
Agustin Escalante¹, Roy W. Haas¹, Daniel F. Battafarano² and Inmaculada Del Rincon³, ¹Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center, San Antonio, TX
Background/Purpose: Cytokines are important in the pathogenesis of RA. Their concentration in the serum rises immediately prior to RA onset, and may be associated with…
Abstract Number: 70 • 2012 ACR/ARHP Annual Meeting
The Impact of Systemic Autoimmune Rheumatic Disease On One-Year Mortality in Congestive Heart Failure Patients: A Population-Level Analysis
Stephanie O. Keeling¹, Asvina Bissonauth¹, Becky Leung² and Padmaja Kaul², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Little is known about the prevalence of systemic autoimmune rheumatic diseases (SARDs) in patients with congestive heart failure (CHF) and its contribution to long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].